Clinical Trial Update: Nicotinic Receptors and Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on nicotinic receptor-targeted approach for schizophrenia and schizoaffective disorder; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Snippet

Sponsor: University of Colorado, Denver | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: COMPLETED | Results posted: 2019-05-07